RALLYBIO CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
RALLYBIO CORPORATION (RLYB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 13.32 thousand shares for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-26
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 12.04K shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 1.28K shares, a 98.37% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was -5.34K shares, a 101.12% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 501.29K shares, a 299.53% increase from fiscal 2023.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 125.47K shares, a 467.60% increase from fiscal 2022.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 22.11K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 12.04K shares derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | 13.32K shares S-4/A · filed 2026-08-26 | 7.97K shares derived: sum of 3 quarters · filed 2026-08-26 | 7.97K shares derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | 1.28K shares S-4 · filed 2026-07-15 | -4.06K shares derived: sum of 2 quarters · filed 2026-08-26 | -4.06K shares derived: sum of 3 quarters · filed 2026-08-26 | -4.06K shares derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | -5.34K shares derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -5.34K shares derived: sum of 2 quarters · filed 2026-08-26 | -5.34K shares derived: sum of 3 quarters · filed 2026-08-26 | 73.48K shares S-4/A · filed 2026-08-26 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-06 | 78.83K shares 10-Q · filed 2025-11-06 | 554.17K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 78.83K shares 10-Q · filed 2025-08-07 | 554.17K shares derived: sum of 3 quarters · filed 2025-08-07 | 562.32K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 78.83K shares 10-Q · filed 2025-05-08 | 554.17K shares derived: sum of 2 quarters · filed 2025-05-08 | 562.32K shares derived: sum of 3 quarters · filed 2025-05-08 | 562.32K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 475.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 483.49K shares derived: sum of 2 quarters · filed 2025-03-13 | 483.49K shares derived: sum of 3 quarters · filed 2025-03-13 | 501.29K shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 8.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 8.15K shares derived: sum of 2 quarters · filed 2024-11-07 | 25.95K shares 10-Q · filed 2024-11-07 | 43.43K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 17.80K shares 10-Q · filed 2024-08-08 | 35.28K shares derived: sum of 3 quarters · filed 2024-08-08 | 35.28K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 17.80K shares 10-Q · filed 2024-05-09 | 35.28K shares derived: sum of 2 quarters · filed 2024-05-09 | 35.28K shares derived: sum of 3 quarters · filed 2024-05-09 | 110.78K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 17.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 17.48K shares derived: sum of 2 quarters · filed 2024-03-12 | 92.98K shares derived: sum of 3 quarters · filed 2024-03-12 | 125.47K shares 10-K · filed 2024-03-12 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 75.50K shares derived: sum of 2 quarters · filed 2023-11-09 | 107.99K shares 10-Q · filed 2023-11-09 | 116.66K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 75.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 107.99K shares 10-Q · filed 2023-08-08 | 116.66K shares derived: sum of 3 quarters · filed 2023-08-08 | |
| 2023-03-31 | 32.49K shares 10-Q · filed 2023-05-09 | 41.16K shares derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2022-12-31 | 8.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 22.11K shares 10-K · filed 2023-03-06 | ||
| 2022-09-30 | 13.44K shares 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |